The Burnet Antiviral Testing facility has the capacity to evaluate chemical agents for inhibitory activity against HIV and herpes simplex (HSV) type 1 and 2 viruses in cell culture assays.
This enables the development of new molecules that may lead to better treatments and/or prophylactics for these chronic infections.
All work undertaken by the facility uses principles outlined in the FDA guidelines for Antiviral Product Development.
Contact: [email protected]